Client News

Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial

Volta Medical Presents Results from First Transatlantic Randomized Controlled Trial Comparing AI-Assisted Ablation Procedure with Conventional Treatment for Persistent Atrial Fibrillation Patients

Integrated DNA Technologies and Molecular Health Ink Commercial Partnership

Medigene AG Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS

MS Pharma Becomes Partner for the Commercialization of FYB203, Formycon’s Biosimilar Candidate to Eylea® (Aflibercept), in the MENA Region

Medigene AG Extends Cash Runway into July 2025 After Successful Oversubscribed Capital Raise

Newron Reports Compelling Additional Data Documenting the Efficacy of Evenamide in Pivotal Study 008A in Poorly Responding Schizophrenia Patients

Volta Medical Featured in Latest Consensus Statement from Leading International Cardiac Electrophysiology Societies on Atrial Fibrillation Ablation

Medigene AG Successfully Raises approximately EUR 5.9 Million in Oversubscribed Capital Measure

InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update